<DOC>
	<DOCNO>NCT00209807</DOCNO>
	<brief_summary>Patients major depressive disorder ( MDD ) commonly many gastrointestinal complaint . Gastrointestinal pain classify 2 category : visceral somatic pain . The main aim study compare somatic visceral sensitivity healthy people pateints MDD . These two sensitivity assess 2 follow test : standardize rectal distension Transdermal transcutaneous electric nerve stimulation . Thereafter , patient MDD randomly allocate escitalopram reboxetine . After 6 week treatment , somatic visceral sensitivity reassess .</brief_summary>
	<brief_title>Effect Escitalopram vs. Reboxetine Gastro-intestinal Sensitivity Patients With Major Depressive Disorder</brief_title>
	<detailed_description />
	<mesh_term>Depression</mesh_term>
	<mesh_term>Depressive Disorder</mesh_term>
	<mesh_term>Depressive Disorder , Major</mesh_term>
	<mesh_term>Hypersensitivity</mesh_term>
	<mesh_term>Abdominal Pain</mesh_term>
	<mesh_term>Reboxetine</mesh_term>
	<mesh_term>Citalopram</mesh_term>
	<mesh_term>Dexetimide</mesh_term>
	<criteria>MDD accord DSMIVTR Hamilton depression scale &gt; 21 history gastrointestinal illness history escitalopram , citalopram reboxetine allergy . history escitalopram , citalopram reboxetine resistant depression . axis I psychiatric disorder . punctuation &gt; 2 suicide item HamD . history ECT past 6 month . pharmacological failure present depressive episode . pregnancy nursing . treatment drug may interact study medication .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>64 Years</maximum_age>
	<verification_date>May 2010</verification_date>
	<keyword>major depression</keyword>
	<keyword>pain</keyword>
	<keyword>escitalopram</keyword>
	<keyword>reboxetine</keyword>
	<keyword>visceral sensitivity</keyword>
	<keyword>somatic sensitivity</keyword>
</DOC>